<DOC>
	<DOC>NCT01756157</DOC>
	<brief_summary>The primary objectives of the study are to evaluate the safety, tolerability, and efficacy of two doses of CINRYZE with recombinant human hyaluronidase (rHuPH20) administered by subcutaneous (SC) injection to prevent angioedema attacks.</brief_summary>
	<brief_title>Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<criteria>Be â‰¥12 years of age. Have a confirmed diagnosis of Hereditary Angioedema. Receipt of any C1 inhibitor (C1 INH) therapy or any blood products for treatment or prevention of an angioedema attack within 7 days before the first dose of study drug. Be receiving prophylactic intravenous CINRYZE that exceeds 1000 units every 3 or 4 days (maximum weekly dose 2000 units). Have received any androgen therapy (e.g., danazol, oxandrolone, stanozolol, testosterone) within 7 days prior to the first dose of study drug. If female, have started taking or changed the dose of any hormonal contraceptive regimen or hormone replacement therapy (i.e., estrogen/progestin containing products) within 3 months prior to the first dose of study drug. History of allergic reaction to C1 INH products, including CINRYZE or other blood products. History of abnormal blood clotting. Have a known allergy to hyaluronidase or any other ingredient in the study formulation.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Crossover</keyword>
	<keyword>Prevention</keyword>
	<keyword>Hereditary Angioedema</keyword>
	<keyword>C1 esterase inhibitor</keyword>
	<keyword>C1 inhibitor</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>Recombinant human hyaluronidase</keyword>
</DOC>